Published in Drug Week, November 11th, 2005
LymphoStat-B reduced the signs and symptoms of SLE at week 52 at a level of statistical significance in seropositive patients, a subgroup that represented 75% of the study's patient population, as measured...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.